Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Products approved by Australia's TGA

27 Feb 2017 07:00

RNS Number : 8584X
Tristel PLC
27 February 2017
 

 

Tristel plc

("Tristel" or the "Company")

 

Fuse for Stella products approved by Australia's Therapeutic Goods Association

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that its Fuse disinfectant used in its Stella decontamination tray has been approved as a high-level disinfectant by Australia's Therapeutic Goods Association ("TGA").

 

Stella and Fuse are specifically designed for the decontamination of small single-channelled instruments, with a particular focus on urology. Flexible cystoscopes are used by urologists for urethral, bladder and kidney examinations and Stella is targeted at this instrument. However, it can also be used to decontaminate bronchoscopes used in respiratory medicine, laryngoscopes used in anaesthesia, manometry catheters used in GI physiology, transoesophageal echo probes used in cardiology, and nasendoscopes used in hospital ear, nose and throat clinics.

 

First introduced to the global hospital market in 2011, 600 Stella systems have been sold worldwide and Fuse and Stella registered £1 million sales for the Company during its last financial year.

 

Stella is a plastic tray sculptured to accommodate cystoscopes whilst occupying minimal work-top space. It is battery-powered, requiring no connection to hospital services and is service / maintenance free. It is the world's only plug and play decontamination concept. Stella achieves all the outcomes of automated endoscope washers at a fraction of their cost and with none of their complexity and operational unreliability. Fuse delivers Tristel's high-level disinfectant into the Stella tray.

 

Tristel has had a presence in the Australian hospital market since 2011 when it received its first approval from the TGA for its Wipes System. From 2011 to 2016 Tristel was represented in the country by a distributor, and in August Tristel purchased the distributor's business and established a direct presence in the Australian hospital market via its wholly-owned subsidiary, Tristel Pty Limited.

 

Paul Swinney, CEO of Tristel plc, comments: "Every regulatory approval gained is a key milestone for Tristel, but this one is particularly exciting. Australia has been a very successful and profitable market for us, and the acquisition of our distributor's business in August 2016 has surpassed expectations. Since the acquisition, we have gained approvals for our Fuse for Surfaces, Jet for Surfaces and Rinse Assure products, and now we have Fuse for Stella to add to the portfolio our team can sell. Australia is a hospital market that has a real need for the Stella decontamination concept, with so many of the country's thousand or so public and private hospitals in remote locations."

 

For further information please contact:

Tristel plc

www.tristel.com

Paul Swinney, Chief Executive 

Tel: 01638 721 500

Liz Dixon, Finance Director

 

 

 

finnCap

 

Geoff Nash / Giles Rolls, Corporate Finance

Tel: 020 7220 0500

Alice Lane, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGZZNVRGNZM
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.